This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Immunotherapy in Urothelial Cancer: Where Are We Now and Where Are We Going?

Immunotherapy in Urothelial Cancer: Where Are We Now and Where Are We Going?


Slide Lecture Series

Time to Complete

1 hour


January 11, 2019


July 11, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

This activity is provided by Creative Educational Concepts.

Commercial Supporter

This activity is supported by an educational grant from AstraZeneca.

Program Description

This educational activity is comprised of four primary sections, all of which seek to address a single overarching question about the clinical utility of immunotherapy in urothelial cancer—where are we now and where are we going? Led by three prominent content experts, this program will explore the current role of immunotherapy in locally advanced and metastatic urothelial cancer, including an overview of all FDA-approved agents and indications. Subsequent sections will discuss the prospective role of immunotherapy in other stages of the disease continuum, with particular emphasis on the potential for novel multimodal and combination regimens to optimize outcomes in late-stage disease, as well as the nascent viability of checkpoint inhibitors as bladder-sparing strategies earlier in the disease spectrum. In an ever-evolving treatment space, which has burgeoned with FDA approvals in recent years and continues to yield an abundance of emerging clinical trial data, this activity seeks to provide clinicians with the knowledge and the tools to provide optimal care for their patients with urothelial cancer.

Intended Audience

This activity is designed to meet the educational needs of urologists and urologic oncologists.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Review current status of checkpoint inhibitor use in urothelial cancer
  • Explore future directions of immunotherapy in urothelial cancer, including the role of sequential therapy and multimodal and/or combination regimens
  • Examine the role of checkpoint inhibitors in non-muscle-invasive, BCG-resistant or BCG-ineligible disease.

Conflict Of Interest Disclosure Policy

In accordance with the Food and Drug Administration, the authors have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


Arjun V. Balar, MD
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

Dr. Balar has disclosed that he is a consultant for AstraZeneca/MedImmune, Genentech, Merck, Pfizer, and Roche. He also receives grant/research support from Genentech, Merck, and Roche.

Ashish M. Kamat, MD, MBBS, FACS
Professor, Department of Urology
Wayne B. Duddlesten Professor of Cancer Research
Associate Cancer Center Director, RFHNH, Mumbai
University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Kamat has disclosed that he is a consultant for Abbott, AstraZeneca, Genentech, and Merck. He also receives grant/ research support from FKD Therapies, Merck, and Photocure.

Neal D. Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Dr. Shore has disclosed that he is a consultant for and receives grant/research support from AstraZeneca, EMD Serono, FKD Therapies, Genentech, Merck, and Pfizer.

Planners and Reviewers Disclosures

Joan B. Fowler, PharmD, BCPP, has no relevant financial relationships to disclose in relation to the content of this activity.

Bryan C. Taylor, PharmD, has no relevant financial relationships to disclose in relation to the content of this activity.

Bishoy Morris Faltas, MD (Weill Cornell Medicine, New York, NY) has no relevant financial relationships to disclose in relation to the content of this activity.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

CEC designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM  .  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.


It is the policy of CEC to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.

Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the learner is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to prescribing, dispensing, or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC for any product or manufacturer identified.


To obtain credit, a score of 65% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Creative Educational Concepts at (866) 360-1717.

If you have any other questions relating to your certificate or other issues with this activity, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue